An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence

Rafia, Rachid, Dodd, Peter J., Brennan, Alan, Meier, Petra S., Hope, Vivian D., Ncube, Fortune, Byford, Sarah, Tie, Hiong, Metrebian, Nicola, Hellier, Jennifer, Weaver, Tim ORCID logoORCID: and Strang, John (2016) An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 111 (9) . pp. 1616-1627. ISSN 0965-2140 [Article] (doi:10.1111/add.13385)

PDF - Published version (with publisher's formatting)
Available under License Creative Commons Attribution-NonCommercial 4.0.

Download (1MB) | Preview


Aims: To determine whether the provision of contingency management using financial incentives to improve hepatitis B vaccine completion in people who inject drugs entering community treatment represents a cost-effective use of healthcare resources.

Design: A probabilistic cost-effectiveness analysis was conducted, using a decision-tree to estimate the short-term clinical and healthcare cost impact of the vaccination strategies, followed by a Markov process to evaluate the long-term clinical consequences and costs associated with hepatitis B infection.

Settings and participants: Data on attendance to vaccination from a UK cluster randomised trial.

Intervention: Two contingency management options were examined in the trial: fixed vs. escalating schedule financial incentives.

Measurement: Lifetime healthcare costs and quality-adjusted life years discounted at 3.5% annually; incremental cost-effectiveness ratios.

Findings: The resulting estimate for the incremental lifetime healthcare cost of the contingency management strategy versus usual care was £22 (95% CI: -£12 to £40) per person offered the incentive. For 1,000 people offered the incentive, the incremental reduction in numbers of hepatitis B infections avoided over their lifetime was estimated at 19 (95% CI: 8 to 30). The probabilistic incremental cost per quality adjusted life year gained of the contingency management programme was estimated to be £6,738 (95% CI: £6,297 to £7,172), with an 89% probability of being considered cost-effective at a threshold of £20,000 per quality-adjusted life years gained (98% at £30,000).

Conclusions: Using financial incentives to increase hepatitis B vaccination completion in people who inject drugs could be a cost-effective use of healthcare resources in the UK as long as the incidence remains above 1.2%.

Item Type: Article
Additional Information: Version of Record online: 6 May 2016
Research Areas: A. > School of Health and Education > Mental Health, Social Work and Interprofessional Learning
Item ID: 19673
Notes on copyright: © 2016 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Useful Links:
Depositing User: Timothy Weaver
Date Deposited: 03 May 2016 11:37
Last Modified: 18 Sep 2020 11:33

Actions (login required)

View Item View Item


Activity Overview
6 month trend
6 month trend

Additional statistics are available via IRStats2.